BioArctic

• BioArctic’s two founders and main shareholders, Lars Lannfelt and Pär Gellerfors, announced the sale of 2,400,000 ordinary shares (equally divided between the sellers), amounting to SEK 720 million in gross proceeds. In connection with the transaction, both sellers have entered into a 180-day lock-up period 
• The sell-down was upsized by 20%, and was priced at SEK 300, a discount of 11.5% vis-à-vis the last closing price of SEK 339, and a 3.1% discount vis-à-vis the 5-day VWAP
• The transaction was launched after several positive news events regarding Leqembi sales and collaborations leveraging the BrainTransporter technology, yielding a significant appreciation of BioArctic’s share price
• The shares sold represent 2.7% of BioArctic’s total shares outstanding with the founders holding a combined stake of 52.2% post divesting a part of their shareholding, thereby remaining the two largest shareholders
• Van Lanschot Kempen is proud to have contributed to a multiple times covered order book which was comprised of both Swedish and international names, and to have actively sustained investor dialogue around the name

BioArctic is a Swedish biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi – the world’s first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer’s disease. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson’s disease and ALS as well as additional projects against Alzheimer’s disease. Several of the projects utilize the company’s proprietary BrainTransporter technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment.

In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

•  Financial Adviser to Galapagos in the sale of a portfolio of oncology and immunology programmes to Onco3R
• Co-Manager in the USD 748 million Capital Increase by Abivax
• Financial Adviser in MaaT Pharma’s €38 million venture debt facility from the European Investment Bank
• Joint Bookrunner in the USD 201 million Capital Increase by Pharvaris
• Lead Manager in the USD 345 million Capital Increase by Merus
• Co-Placement Agent in DBV Technologies’ up to USD 307 million financing
• Placement Agent in MaaT Pharma’s €13 million capital increase
• Sole Financial Adviser in Pharming’s SEK 725 million public takeover of Abliva
• Sole Financial Adviser in GENFIT’s royalty financing up to €185 million
• Sole Financial Adviser in IO Biotech’s c. €58 million loan facility from the European Investment Bank
• Financial Adviser in the USD 479 million US Public Offering by NewAmsterdam Pharma
• Sole Financial Adviser to SNIPR Biome in securing a €20 million venture debt facility from the European Investment Bank